ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Short Interest Update

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) recently experienced a significant reduction in short interest for the month of November. As of November 15, the short interest stood at 28,900 shares, reflecting a decrease of 36.5% from the end of October, which recorded a total short interest of 45,500 shares. Given an average trading volume of approximately 1,220,000 shares, the short-interest ratio has effectively dropped to 0.0 days. Currently, around 2.7% of the company's shares are reported as sold short.

ZyVersa Therapeutics Stock Performance

On Friday, shares of NASDAQ:ZVSA opened at $1.07. The stock has experienced fluctuations over the past year, with a low of $1.03 and a high reaching $42.39. The fifty-day simple moving average currently stands at $1.90, while the 200-day simple moving average is at $3.13.

ZyVersa Therapeutics Company Profile

ZyVersa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on developing and bringing to market treatment options for renal and inflammatory diseases. Among its initiatives is a drug called Cholesterol Efflux Mediator VAR 200, which is injectable and is currently in Phase 2a trials targeting renal issues like focal segmental glomerulosclerosis, Alport syndrome, and diabetic kidney diseases. Additionally, the company is working on Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is still in the preclinical stage, aiming to address a range of inflammatory diseases, including acute respiratory syndrome, multiple sclerosis, IgA nephropathy, pancreatic cancer, as well as neurodegenerative diseases like Parkinson's and Huntington's, along with others such as atherosclerosis, Alzheimer’s disease, and obesity.

ZyVersa, stocks, shortinterest